As the CEO of NJ Labs, I am thrilled to be part of a cutting-edge, highly competitive industry that is constantly evolving. Not only do new technologies advance at incredible rates, but the science itself is continually in flux. Just when you think that steady ground has been reached, a new breakthrough technology or medication emerges that overturns prior assumptions. The caveat here is that in this kind of environment, the need to stay competitive and reduce cost is often prioritized at the expense of quality with the end consumer often being forgotten.
At NJ Labs, our clients will always be our priority and compromising on quality is not an option. I strongly believe compromising on quality puts both our clients and ultimately the end consumer at risk. To help our clients remain innovative and competitive while meeting rigorous compliance requirements, we have continued to grow our expertise and to develop quality systems grounded in transparency, integrity, and honesty.
For example, over the past several years, we have completed major improvements to our facilities and laboratory equipment. We have also grown our staff by over 100 percent to accommodate stringent testing criteria. And we have rigorously trained all our employees on our extensive instrument inventory. We also routinely collaborate with manufacturers to stay ahead of the information and technology curve. We have developed an extensive library of internal Standard Operating Procedures (SOPs) and continue to expand our test capabilities and methodologies in analytical chemistry and microbiology.
Most recently, we have delved into the uncharted territory of CBD, cannabis, and hemp testing; taking on the challenge of using complex instrumentation to validate and analyze samples for heavy metals, potency, microbiology, and toxins in a CGMP facility. NJ Labs will continue to pursue the potential of this growing industry.
For over eighty years, we have continued to grow with our clients to meet their research and development needs while addressing the aggressive increase in demands from regulatory bodies. We are prepared and excited to be a part of our clients’ growth and progression as we continue into the 21st century.
Chief Executive Officer